RIGI and neoplasm: To overcome these challenges, we present a strategy that involves the intracellular assembly of the RIG-I agonist on a tumor-specific RNA template (e.g., miRNA-21) by delivering a 5'-triphosphate single-stranded RNA RIG-I agonist (RIGA-miRNA-21) by a superparamagnetic nanoparticle carrier (TTX) to initiate specific RIG-I signaling and antitumor immune responses.